A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced malignant pleural mesothelioma

Lung Cancer

Volumn 81, Issue 3, 2013, Pages 422-427

  Nowak, Anna K ^a,b,c   Brown, Chris ^d   Millward, Michael J ^a,b   Creaney, Jenette ^b,c   Byrne, Michael J ^a,b,c   Hughes, Brett ^e   Kremmidiotis, Gabriel ^f   Bibby, David C ^f   Leske, Annabell F ^f   Mitchell, Paul L R ^g   Pavlakis, Nick ^h,i   Boyer, Michael ^j   Stockler, Martin R ^d  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c National Centre for Asbestos Related Diseases   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e THE PRINCE CHARLES HOSPITAL   (Australia)

^f Bionomics   (Australia)

^g AUSTIN HEALTH   (Australia)

^h ROYAL NORTH SHORE HOSPITAL   (Australia)

ⁱ University of Sydney   (Australia)

^j ROYAL PRINCE ALFRED HOSPITAL   (Australia)

more..

Author keywords

Biomarkers; BNC105P; Clinical trial; Mesothelioma; Phase II; Vascular Disrupting Agent

Indexed keywords

6 METHOXY 2 METHYL 3 (3,4,5 TRIMETHOXYBENZOYL)BENZOFURAN 7 YL PHOSPHATE DISODIUM; PEMETREXED;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CARDIOPULMONARY INSUFFICIENCY; DEATH; DRUG EFFICACY; DRUG SAFETY; ELECTROCORTICOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TREATMENT RESPONSE;

BIOMARKERS; BNC105P; CLINICAL TRIAL; MESOTHELIOMA; PHASE II; VASCULAR DISRUPTING AGENT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZOFURANS; BIOLOGICAL MARKERS; FEMALE; GPI-LINKED PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; ORGANOPHOSPHATES; PLEURAL NEOPLASMS; TREATMENT OUTCOME; TUBULIN MODULATORS; TUMOR BURDEN;

EID: 84881663491     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.05.006     Document Type: Article

References (24)

1. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
2. Yasumitsu A., Tabata C., Tabata R., Hirayama N., Murakami A., Yamada S., et al. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol 2010, 5:479-483.
3. Kumar-Singh S., Vermeulen P.B., Weyler J., Segers K., Weyn B., Van Daele A., et al. Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma V. J Pathol 1997, 18:211-216.
4. König J.-E., Tolnay E., Wiethege T., Müller K.M. Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma. Virchows Arch 1999, 435:8-12.
5. Siemann D.W. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev 2011, 37:63-74.
6. Kremmidiotis G., Leske A.F., Lavranos T.C., Beaumont D., Gasic J., Hall A., et al. BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy. Mol Cancer Ther 2010, 9:1562-1573.
7. Rischin D., Bibby D.C., Chong G., Kremmidiotis G., Leske A.F., Matthews C.A., et al. Clinical, pharmacodynamic and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation. Clin Cancer Res 2011, 17:5152-5160.
8. Byrne M.J., Nowak A.K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004, 15:257-260.
9. Creaney J., Olsen N.J., Brims F., Dick I.M., Musk A.W., de Klerk N.H., et al. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev 2010, 19:2238-2246.
10. Brookmeyer R., Crowley J. A confidence interval for the median survival time. Biometrics 1982, 38:29-41.
11. Creaney J., Francis R.J., Dick I.M., Musk A.W., Robinson B.W., Byrne M.J., et al. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res 2011, 17:1181-1189.
12. Kindler H.L., Karrison T.G., Gandara D.R., Lu C., Krug L.M., Stevenson J.P., et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 2012, 30:2509-2515.
13. Jackman D.M., Kindler H.L., Yeap B.Y., Fidias P., Salgia R., Lucca J., et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008, 113:808-814.
14. Laurie S.A., Gupta A., Chu Q., Lee C.W., Morzycki W., Feld R., et al. Brief report: a phase II study of sunitinib in malignant pleural mesothelioma: the NCIC Clinical Trials Group. J Thorac Oncol 2011, 6:1950-1954.
15. Garland L.L., Chansky K., Wozniak A.J., Tsao A.S., Gadgeel S.M., Verschraegen C.F., et al. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thorac Oncol 2011, 6:1938-1945.
16. Stevenson J.P., Rosen M., Sun W., Gallagher M., Haller D.G., Vaughn D., et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003, 21:4428-4438.
17. Rustin G.J.S., Galbraith S.M., Anderson H., Stratford M., Folkes L.K., Sena L., et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003, 21:2815-2822.
18. Dowlati A., Robertson K., Cooney M., Petros W.P., Stratford M., Jesberger J., et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002, 62:3408-3416.
19. Zwiefel M., Jayson G.C., Reed N., Osborne R., Hassan B., Shereeves G., et al. Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: final phase II trial results. J Clin Oncol 2009, 27(15s). Abstr 5502.
20. Lara P.N., Douillard J.-Y., Nakagawa K., von Pawel J., McKeage M.J., Albert I., et al. Randomized phase III Placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 2011, 29:2965-2971.
21. Jassem J., Ramlau R., Santoro A., Schuette W., Chemaissani A., Hong S., et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008, 26:1698-1704.
22. Zucali P.A., Ceresoli G.L., Garassino I., De Vincenzo F., Cavina R., Campagnoli E., et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 2008, 112:1555-1561.
23. Giaccone G., O'Brien M.E., Byrne M.J., Bard M., Kaukel E., Smit B. Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur J Cancer 2002, 38(Suppl. 8):S19-S24.
24. Nowak A.K., Millward M.J., Creaney J., Francis R.J., Dick I.M., Hasani A., et al. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. J Thorac Oncol 2012, 7:1449-1456.